亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

1397 ATG 027 a first in class B7 H3 PD L1 bispecific antibody shows potent T cell activation capability and in vivo anti tumor efficacy

作者
Hui Yuwen,Tengteng Li,Yijing Ren,Linjie Tian,Jay M. Mei,Bo Shan,Bing Hou
出处
期刊:Journal for ImmunoTherapy of Cancer [BMJ]
卷期号:: A1452-A1452 被引量:2
标识
DOI:10.1136/jitc-2022-sitc2022.1397
摘要

Background Programmed death-ligand 1 (PD-L1) and programmed cell death protein 1(PD-1) blockade therapy has been approved for the treatment of many malignancies whereas the majority of patients with solid tumors do not respond well.1 B7-H3, another newly identified immune checkpoint molecule, has limited expression in normal human tissues while highly expressed on cancer cells and tumor-infiltrating antigen-presenting cells (APCs), which is associated with T-cell exhaustion in cancer patients. In addition, B7-H3 is overexpressed by the tumor-associated vasculature and stromal fibroblasts, and contributes to the development of cancer through both immune-dependent and nonimmune routes.2 However, clinical therapeutic antibodies targeting B7-H3, such as Enobituzumab, have not shown an immune checkpoint blockade effect. ATG-027, a novel B7-H3/PD-L1 bispecific antibody, was designed to exert the anti-tumor efficiency through reinforcing T cell activation by dual-blocking of B7-H3 and PD-L1, antibody-dependent cellular cytotoxicity (ADCC), complement dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP). Methods ATG-027 was developed by introducing high-affinity PD-L1 scFv into a human IgG1 B7-H3 monoclonal antibody (mAb). The bispecific antibody employed wild type Fc domain which enables ADCC and ADCP effects. A series of in vitro studies were performed to evaluate the immune regulating function and anti-tumor efficacy of ATG-027. The in vivo efficacy of ATG-027 was evaluated in mice bearing syngeneic MC38 colorectal cancer cells overexpressing human B7-H3 (MC38-hB7-H3). Results In the cell-based assay, ATG-027 binds with nanomolar affinity to both B7-H3 and PD-L1 expressing cells. ATG-027 demonstrated higher ADCC/CDC activity compared with anti-PD-L1 and anti-B7-H3 parental antibodies. ATG-027 also demonstrated greater ADCP potency than anti-PD-L1, anti-B7-H3, or the combination. Interestingly, in a Mixed Lymphocyte Reaction (MLR) experiment to assess the T cell activation, the B7-H3 parental antibody (30-C7) or the Fab region of 30-C7 (30-C7-Fab) induced robust IL-2 and IFNγ production, indicating T cell activating function, whereas Enobituzumab showed no effect in the experiment (figure 1). ATG-027 also demonstrated superior in vivo anti-tumor activity in mouse MC38-hB7-H3 models compared to parental antibodies. Biweekly dosing of 7.5mg/kg ATG-027 induced tumor shrinkage or complete tumor regression. Conclusions By binding to a specific epitope of B7-H3, ATG-027 blocks the protein’s inhibitory function, leading to strong T cell activation. ATG-027 can also inhibit the interaction between PD1/PD-L1 to rescue T cell activity suppression. ATG-027’s dual T cell activation function and powerful ADCC, CDC, and ADCP properties contribute to its promising anti-tumor efficacy in preclinical models. References Cai D, J Li, D Liu, S Hong, Q Qiao, Q Sun, P Li, N Lyu, T Sun, S Xie, L Guo, L Ni, L Jin, and C Dong. Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy. Cellular & Molecular Immunology 2020;17: 227–236. Zhou WT, and WL Jin. B7-H3/CD276: An Emerging Cancer Immunotherapy. Frontiers in Immunology 2021;12: 701006. Ethics Approval The protocol and any amendment(s) or procedures involving the care and use of animals in this study were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of CrownBio to execution with an AUP number or IACUC approval number for each animal study.All studies were conducted following an approved IACUC protocol. AUP NO. 2104-09-2186.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6.4的应助被u102060采纳,获得10
1秒前
null的应助被科研通管家采纳,获得50
1秒前
科研通AI6.3的应助被u264877采纳,获得10
4秒前
机智的白卉的应助被u102060采纳,获得10
9秒前
李健的应助被u680513采纳,获得10
11秒前
优雅谷蕊完成签到,获得积分10
15秒前
odd完成签到,获得积分10
18秒前
科研通AI6.2的应助被u102060采纳,获得10
19秒前
余凌兰完成签到 ,获得积分10
19秒前
syvshc的应助被u680513采纳,获得10
21秒前
领导范儿的应助被u855744采纳,获得10
23秒前
超级的迎梅完成签到,获得积分10
35秒前
机智的白卉的应助被u680513采纳,获得10
37秒前
科研通AI6.3的应助被u680513采纳,获得10
41秒前
小蘑菇的应助被吴彦祖采纳,获得10
45秒前
49秒前
科研通AI6.4的应助被u855744采纳,获得10
55秒前
科研通AI6.3的应助被u855744采纳,获得10
57秒前
科研通AI6.3的应助被u264877采纳,获得10
57秒前
科研通AI6.2的应助被u855744采纳,获得10
59秒前
科研通AI6.3的应助被u855744采纳,获得10
59秒前
科研通AI6.2的应助被u264877采纳,获得10
1分钟前
科研通AI6.3的应助被u264877采纳,获得10
1分钟前
风吹麦浪的应助被u583484采纳,获得10
1分钟前
科研通AI6.3的应助被u264877采纳,获得10
1分钟前
漂亮的新梅完成签到,获得积分10
1分钟前
七七完成签到 ,获得积分10
1分钟前
忧郁的数据线关注了科研通微信公众号
1分钟前
1分钟前
syvshc的应助被u721406采纳,获得10
1分钟前
u588294驳回了852的应助
1分钟前
1分钟前
1分钟前
遇上就这样吧给u266829的求助进行了留言
1分钟前
顺利手链完成签到,获得积分10
1分钟前
生动的昊焱完成签到,获得积分10
1分钟前
阿切尔代的应助被科研通管家采纳,获得10
2分钟前
2分钟前
2分钟前
吴彦祖发布了新的文献求助10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185144
求助须知:如何正确求助?哪些是违规求助? 9574052
关于积分的说明 21834129
捐赠科研通 7782640
什么是DOI,文献DOI怎么找? 3434531
关于科研通互助平台的介绍 2558762
邀请新用户注册赠送积分活动 2481206